// App-Quantinova.ai

e19512 : The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

Researchers

Presenter

  • Sophie van Beekhuizen

Principal Investigators

  • Yannan Hu

  • Ana Gezin

  • Bart Heeg

  • Timothy Bell

  • Majed Charaan

  • Andrew Brown

  • Geoffrey Chan

  • Joseph C Cappelleri

Medical Centers

  • Ingress Health, Rotterdam, Netherlands

  • Ingress Health, Rotterdam, Netherlands

  • Ingress Health, Rotterdam, Netherlands

  • Pfizer Inc, New York, NY

  • Merck, Kirkland, QC, Canada

  • Pfizer Canada Inc, Kirkland, QC, Canada

  • Pfizer, Groton, CT

Locations

  • Netherlands

  • United States

  • Canada

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Vidaza

  • Cytarabine liposomal

  • glasdegib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved